NextCure begins dose optimization study for ovarian cancer drug

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/24/2026

1. SPCX
2. META
3. ABBV
4. SPY
5. FDX
6. IBM
7. NKE
8. MU
9. PFE
10. AWK

Go back to NextCure begins dose optimization study for ovarian cancer drug
(NASDAQ: NXTC) Delayed: 1.81 +0.06 (3.43%)
Previous Close $1.75    52 Week High $ 
Open $1.70    52 Week Low $ 
Day High $1.90    P/E N/A 
Day Low $1.65    EPS $ 
Volume 163,688